Search
vilanterol
Indications:
- used in combination with umeclidinium in Anoro, an inhaler for treatment of COPD
* safe for patients with cardiovascular disease
Mechanism of action:
- long-acting beta-2 adrenergic receptor agonist
Interactions
drug adverse effects of adrenergic receptor agonists
General
inhaled beta-2 adrenergic receptor agonist
References
- Physician's First Watch, May 1, 2013
David G. Fairchild, MD, MPH, Editor-in-Chief
Massachusetts Medical Society
http://www.jwatch.org
- FDA News Release: May 10, 2013
FDA approves Breo Ellipta to treat chronic obstructive
pulmonary disease
- Vestbo J, Anderson JA, Brook RD et al
Fluticasone furoate and vilanterol and survival in chronic
obstructive pulmonary disease with heightened cardiovascular
risk (SUMMIT): a double-blind randomised controlled trial.
Lancet. 2016 Apr 30;387(10030):1817-26.
PMID: 27203508
- Brusselle G.
Vilanterol fluticasone and mortality in comorbid COPD GOLD B.
Lancet. 2016 Apr 30;387(10030):1791-2. Epub 2016 Apr 28.
PMID: 27203487
Component-of
umeclidinium/vilanterol (Anoro Ellipta)